SVR₁₂ according to baseline patient characteristics and on-treatment HCV viral decline.

SVR12 according to baseline patient characteristics and on-treatment HCV viral decline.</p

Baseline patient characteristics.

Baseline patient characteristics.</p

Virologic responses.

Virologic responses.</p

SVR₁₂ in patients of specific interest.

SVR12 in patients of specific interest.</p

Study flow.

Study flow.</p

Safety summary.

Safety summary.</p

Additional file 4 of Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Additional file 4: Table S4. Comparison of Level 2 KEGG pathways

Additional file 1 of Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Additional file 1: Table S1. Statistical significance of beta diversity distance matrices

Additional file 3 of Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Additional file 3: Table S3. The average abundance of predicted Level 2 KEGG pathways in each group

Additional file 6 of Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Additional file 6: Figure S2. Beta diversity indices of patients with HBeAgchronic HBV infection, HBeAgchronic hepatitis B, HBeAgchronic HBV infection, HBeAgchronic hepatitis B, and resolved HBV. A PCoA plot of bacterial beta diversity based on the weighted UniFrac distance. B PCoA plot of bacterial beta diversity based on the unweighted UniFrac distance. No separate cluster was found between HBeAgchronic HBV infection, HBeAgchronic hepatitis B, HBeAgchronic HBV infection, HBeAgchronic hepatitis B, and resolved HBV